Aconte completed the A round of nearly 100 million financing, by Sequoia China, Sherpa, Fosun, Songyu, Yuansheng Ventures, Hengqin Jin investment.

Guide: Financial help, Ayconte a number of eye-vision products will soon be facing.
, a research and development enterprise dedicated to a full range of innovative solutions for medical devices in the field of ophthalmology and ophthalmology, Icant Medical Technology Co., Ltd. ("Icant"), recently completed round A financing, and has locked up the A-plus round of financing, the total financing amount of more than 100 million yuan.
round of financing is led by Sequoia Capital China Fund, Sherba Investment, Fosun Ventures, Songyu Capital, Yuansheng Ventures, Hengqin Jin Investment and other joint investments.
funds will be used to accelerate the development, clinical and registration process of Aconte's many eye-vision medical device products.
Aconte is a unique manufacturer of eye vision medical devices, its eye vision solutions mainly related to adolescent myopia prevention and control, adult vision correction and treatment of eye watch diseases, contact lens full-service care products and eye vision examination equipment.
its research and development production, including scleral mirror, including a number of equipment products, are the first to launch, fill the gaps in the industry products.
do we involve medical devices in the field of ophthalmopia? Guosheng Securities reports that there are more than 2.2 billion blind and visually impaired people worldwide.
China is the world's largest number of eye disease patients, myopia, dry eye disease, cataracts alone, the number of patients with the three major eye diseases more than 1 billion (regardless of overlapping incidence).
2019, the overall size of China's ophthalmology market reached 170 billion yuan, of which 124 billion yuan in the ophthalmology medical market, 26.7 billion yuan in the ophthalmology device market, and 19.3 billion yuan in the ophthalmology drug market.
because of the current popularity of mobile phones, tablets and other electronic products so that the number of people with myopia increased, and the aging of the population led to cataracts, glare and other eye diseases increased.
the domestic ophthalmology medical market is growing at a rate of 15%.
, the market value of ophthalmology equipment production and development enterprises in the field of ophthalmology and light is growing rapidly.
years of experience and industry awareness, so that founder Li Xiao micro determined to quickly form a team into the field of eye-vision medical devices.
In the ophthalmology industry giant Erkang, according to the road optics experience let Li Xiao micro realize that the current field of eye and vision is basically led by foreign enterprises in the market, domestic enterprises although trying to achieve domestic replacement, but lack of innovative technology.
invited the world's top research and development team in the field of eye vision, using innovative technology to build devices and continuously expand the product chain.
believes that through differentiated product creation, full solution delivery and efficient market strategy operations, Aicant can continue to deliver value to the industry.
its products have been approved and accepted by clinicians.
Isaconte is also conducting clinical trials with a number of top hospitals in China, trying to break the situation of foreign companies leading the industry and achieve domestic substitution through the continuous introduction of innovative medical devices in the field of ophthalmology and light.
do you like Erconte? In the process of development, Aconte will gradually form four major sectors of business.
complement each other across the various sectors of the industry to build a complete set of innovative eye and optical medical device solutions.
National Visual Health Report predicts that by 2020 the number of myopia cases over the age of 5 in China will exceed 700 million, and the number of people with high myopia will reach 40 million to 51.55 million.
said the number of young people with myopia could be as high as 84.08 million.
they will be potential consumer users.
for myopia prevention and control in adolescents, Aconte's product pipelines include corneal plastic mirrors (OK mirrors) and multi-focus corneal contact lenses (Muti-focalRGP).
Ercont introduced innovative design OK mirrors that use partitioning, special optical area design, and AI testing to differentiate between existing products in the market for increased effectiveness, safety, and simplified testing processes.
market OK mirror penetration rate of only 1.37%, the overall market size of 2.03 billion, but the market with more than 20% growth rate to achieve growth.
will seep into the market through differentiated design OK mirrors.
is about to launch a multi-focus RGP for patients who are highly nearscopic astoralyzed or unfit to wear OK mirrors at night.
focus RGP market is still in its early stages, but in the future multi-focus RGP will cover 15% of the youth myopia prevention and control market.
for adult vision correction and eyelid disease, Esconte is about to launch RGP and the country's first sclere mirror product.
scleral mirror will fill the gap in the domestic industry.
moderate to severe conical cornea, as well as a variety of causes of eyelid closure is incomplete, corneal transplantation, trauma and other postoperative eyelid repair and vision correction patients have rigid demand for scleoscopes.
the various causes of corneal irregular astration, moderate to severe dry eye disease, wearing a sclerosis mirror is the preferred corrective and therapeutic methods.
, according to expert interviews, at least 21 million patients in the domestic market can receive sclera mirror treatment.
the global market price of scleral mirror, scleral mirror market value scale will be no less than OK mirror.
the current global sclerine mirror market also continues to maintain more than 20% growth, by 2025 the global sclerine mirror sales are expected to be 3.6 million pieces, which means a broad market space for Aconte.
is also opening two new business segments, including a full range of contact lens care products and eye-vision-related inspection equipment.
full range of care products is an accessory to contact lenses, which are used in conjunction with contact lenses to help Aconte products expand better and faster in the future.
visual inspection equipment will be launched as a marketing tool for Esconte products, including wide-angle front section OCT, eye shaft biometrics and so on.
the research and development of wide-angle pre-section OCT will be closely combined with the evaluation of the effect of scleral mirror, greatly improving the efficiency of scleral mirror matching.
synergies will be generated by the four segments of The Year's Eye Vision Devices.
Li said, "Let every eye-vision patient from the beginning of the hospital, have access to high-quality products from Aconte services", which is the layout strategy of Esconte.
addition, Esconte also hopes to work with more visual and optical research and development talents, experts and peers in the future to further strengthen the product development pipeline and give full play to the industrial aggregation effect.
"Thank you very much to Sequoia China, Sherba, Fosun, Songyu, Yuansheng Ventures, Hengqin Jin Investment and other investors for their recognition of Ikant, " said Li Xiao micro, founder of Aikonte.
they have a deep understanding of the healthcare industry and will give Esconte a deeper market insight and broader strategic planning.
this financing will help Esconte better and faster achieve its vision of becoming a provider of a full range of solutions in the field of ophthalmopathic devices through leading technology for the benefit of the vast number of eye and optical patients in China.
we have confidence in that.
", another founder of Erconte Fu Xiaoyang was the founder of the well-known medical device CRO Jetcom.
has helped several international optical and optical medical companies enter China over the past two decades.
: "Focusing on investing in and developing innovative medical devices has been my dream for many years, and this collaboration with Li Xiaoxuan is a combination of pearls."
we are confident that we can rapidly promote the development and listing of Aconte products to help the development of China's eye and optical industry.
, managing director of Sequoia Capital China Fund, the lead investor in the A-round, said: "Eye-vision diseases have a large number of patients and rigid clinical needs.
china's eye and optical medical device market is in a rapid growth stage.
Ayconte has laid out a rich product line in this field, the goal is to develop products with domestic performance leading or filling the gaps in domestic products.
Sequoia Capital will continue to support companies in furthering their growth through research and acquisitions.
" Angel Wheel Investor on behalf of Sherba Investment Vice President Deng Wei said: "Since the establishment of Aicant, the rapid formation of the domestic first-class research and development, registration, sales team, proving the team's executive power and market competitiveness.
sherba will actively help Aconte to jointly promote the development of the cause of ophthalmological disease prevention and treatment in China.
"